drugset / Trial / NCT05093205

STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS

NCT05093205

Phase 1 Completed 35 enrolled Pfizer
Non-randomizedSequentialOpen-labelBasic science

Summary

The purpose of this study is to characterize the effect of PF-06882961, administered at 2 steady-state dose levels, on the PK of single doses of atorvastatin (20 mg) or midazolam (5 mg), administered separately, in healthy adult male and female participants (Part A), or an OC in healthy PM female participants (Part B).

Timeline

Start
2021-10-25
Primary completion
2022-07-06
Completion
2022-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 20 mg Oral
Subject Danuglipron Small molecule
Subject Levonorgestrel Small molecule 0.15 mg Oral
Subject Midazolam Small molecule 5 mg Oral
Subject ethinyl estradiol Small molecule 0.03 mg Oral

Indications

No indication recorded.